The biology and therapeutic potential of the DDAH/ADMA pathway

Current Pharmaceutical Design

Volumn 16, Issue 37, 2010, Pages 4089-4102

  Arrigoni, F ^a   Ahmetaj, B ^a   Leiper, J ^b  

^a KINGSTON UNIVERSITY   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Asymmetric dimethylarginine; Cardiovascular; Dimethylarginine dimethylaminohydrolase; Endothelium; Nitric oxide

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ARGININE; ATORVASTATIN; BRADYKININ; C REACTIVE PROTEIN; DIMETHYLARGININASE; EPROSARTAN; FENOFIBRATE; GW 4046; INSULIN; KAEMPFEROL; LOW DENSITY LIPOPROTEIN; METFORMIN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PIOGLITAZONE; PRAVASTATIN; PROBUCOL; RETINOL; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; TAURINE; TELMISARTAN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VALSARTAN;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME SYNTHESIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIVER METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; URINARY EXCRETION; VITAMIN SUPPLEMENTATION;

AMIDOHYDROLASES; ANIMALS; ARGININE; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; MOLECULAR TARGETED THERAPY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 79952715746     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794519246     Document Type: Article

References (234)

1. McBride AE, Silver PA. State of the arg: protein methylation at arginine comes of age. Cell 2001; 106(1): 5-8.
2. Boger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87(2): 99-105.
3. Chen Y, Xu X, Sheng M, Zhang X, Gu Q, Zheng Z. PRMT-1 and DDAHs-induced ADMA upregulation is involved in ROS- and RAS-mediated diabetic retinopathy. Exp Eye Res 2009; 89(6):1028-1034.
4. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 2003; 42(5): 985-990.
5. Sasser JM, Moningka NC, Cunningham MW, Jr., Croker B, Baylis C. Asymmetric dimethylarginine in angiotensin II-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2010; 298(3):R740-R746.
6. Leiper J, Vallance P. New tricks from an old dog: nitric oxide independent effects of dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2006; 26(7): 1419-1420.
7. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24(6): 1023-1030.
8. Bedford MT, Richard S. Arginine methylation an emerging regulator of protein function. Mol Cell 2005; 18(3): 263-272.
9. Hasegawa K, Wakino S, Tanaka T, et al. Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Sp1 transcription factor in endothelial cells. Arterioscler Thromb Vasc Biol 2006; 26(7): 1488-1494.
10. Murray-Rust J, Leiper J, McAlister M, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 2001;8(8): 679-683.
11. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20(9): 2032-2037.
12. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997; 1(1): 65-73.
13. Broer A, Wagner CA, Lang F, Broer S. The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine. Biochem J 2000; 349 Pt 3: 787-795.
14. Bogle RG, MacAllister RJ, Whitley GS, Vallance P. Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol 1995; 269(3 Pt 1): C750-C756.
15. Cardounel AJ, Cui H, Samouilov A, et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007; 282(2): 879-887.
16. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the L-arginine paradox and acts as a novel cardiovascular risk factor. J Nutr 2004; 134(10 Suppl):2842S-2747S; discussion 53S.
17. Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: Regulation and action. Pharmacol Res 2009; 60(6): 448-460.
18. Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 2003; 83(1): 183-252.
19. Parnell MM, Chin-Dusting JP, Starr J, Kaye DM. In vivo and in vitro evidence for ACh-stimulated L-arginine uptake. Am J Physiol Heart Circ Physiol 2004; 287(1): H395-400.
20. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 Suppl 12: S60-S62.
21. Sessa WC, Harrison JK, Luthin DR, Pollock JS, Lynch KR. Genomic analysis and expression patterns reveal distinct genes for endothelial and brain nitric oxide synthase. Hypertension 1993; 21(6Pt 2): 934-938.
22. Busse R, Mulsch A. Calcium-dependent nitric oxide synthesis in endothelial cytosol is mediated by calmodulin. FEBS Lett 1990;265(1-2): 133-136.
23. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990; 87(24): 10043-10047.
24. Moncada S, Higgs EA. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol 2006; (176 Pt 1): 213-254.
25. Murad F, Mittal CK, Arnold WP, Katsuki S, Kimura H. Guanylate cyclase: activation by azide, nitro compounds, nitric oxide, and hydroxyl radical and inhibition by hemoglobin and myoglobin. Adv Cyclic Nucl Res 1978; 9: 145-158.
26. Clementi E. Role of nitric oxide and its intracellular signaling pathways in the control of Ca2+ homeostasis. Biochem Pharmacol 1998; 55(6): 713-718.
27. Eardley I. The role of phosphodiesterase inhibitors in impotence. Expert Opin Investig Drugs 1997; 6(12): 1803-1810.
28. Assreuy J, Cunha FQ, Liew FY, Moncada S. Feedback inhibition of nitric oxide synthase activity by nitric oxide. Br J Pharmacol 1993; 108(3): 833-837.
29. Yasinska IM, Kozhukhar AV, Sumbayev VV. S-nitrosation of thioredoxin in the nitrogen monoxide/superoxide system activates apoptosis signal-regulating kinase 1. Arch Biochem Biophys 2004; 428(2): 198-203.
30. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science (New York, NY) 1992;258(5090): 1898-1902.
31. Lee JR, Kim JK, Lee SJ, Kim KP. Role of protein tyrosine nitration in neurodegenerative diseases and atherosclerosis. Arch Pharmacol Res 2009; 32(8): 1109-1118.
32. Venardos K, Zhang WZ, Lang C, Kaye DM. Effect of peroxynitrite on endothelial L-arginine transport and metabolism. Int J Biochem Cell Biol 2009; 41(12): 2522-2527.
33. Cooke JP. Flow, NO, and atherogenesis. Proc Natl Acad Sci USA 2003; 100(3): 768-770.
34. Murohara TAT. Nitric oxide and angiogenesis in cardiovascular disease. Antioxid Redox Signal 2002; 4(5): 825-831.
35. Goligorsky MS, Abedi H, Noiri E, et al. Nitric oxide modulation of focal adhesions in endothelial cells. Am J Physiol 1999; 276(6 Pt1): C1271-C1281.
36. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev 2006;7(5): 359-371.
37. Murohara T, Asahara T. Nitric oxide and angiogenesis in cardiovascular disease. Antioxid Redox Signal 2002; 4(5): 825-831.
38. Dowling RB, Newton R, Robichaud A, Cole PJ, Barnes PJ, Wilson R. Effect of inhibition of nitric oxide synthase on Pseudomonas aeruginosa infection of respiratory mucosa in vitro. Am J Respir Cell Mol Biol 1998; 19(6): 950-958.
39. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, Imaizumi T. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 2003; 92(2): 226-233.
40. Boger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin Chem Lab Med 2003; 41(11): 1467-1472.
41. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97(5): e53-e59.
42. Tanaka M, Sydow K, Gunawan F, et al. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 2005; 112(11): 1549-1556.
43. Wells SM, Holian A. Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells. Am J Respir Cell Mol Biol 2007; 36(5): 520-528.
44. Jiang DJ, Jia SJ, Dai Z, Li YJ. Asymmetric dimethylarginine induces apoptosis via p38 MAPK/caspase-3-dependent signaling pathway in endothelial cells. J Mol Cell Cardiol 2006; 40(4): 529-539.
45. Furukawa Y, Kimura T. Hypertension in patients with ischemic heart disease. Nippon Rinsho 2004; 62 (Suppl 3): 465-470.
46. Grattagliano I, Portincasa P, Caraceni P, et al. Experimental observations and clinical implications of fasting and diet supplementation in fatty livers. Eur Rev Med Pharmacol Sci 2003; 7(1): 1-7.
47. Jiang JL, Zhang XH, Li NS, et al. Probucol decreases asymmetrical dimethylarginine level by alternation of protein arginine methyltransferase I and dimethylarginine dimethylaminohydrolase activity. Cardiovasc Drugs Ther 2006; 20(4): 281-294.
48. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339(8793): 572-575.
49. Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 851(1-2): 42-50.
50. Billecke SS, D'Alecy LG, Platel R, et al. Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease. Nephrol Dial Transplant 2009; 24(2): 489-496.
51. Fleck C, Schweitzer F, Karge E, Busch M, Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta 2003; 336(1-2): 1-12.
52. Marescau B, Nagels G, Possemiers I, et al. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 1997; 46(9): 1024-1031.
53. Nijveldt RJ, Van Leeuwen PA, Van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant 2002; 17(11): 1999-2002.
54. Schmidt RJ, Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000; 58(3): 1261-1266.
55. Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343 Pt 1: 209-214.
56. Tran CT, Fox MF, Vallance P, Leiper JM. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 2000; 68(1): 101-105.
57. Kimoto M, Tsuji H, Ogawa T, Sasaoka K. Detection of NG, NG dimethylarginine dimethylaminohydrolase in the nitric oxidegenerating systems of rats using monoclonal antibody. Arch Biochem Biophys 1993; 300(2): 657-662.
58. Nijveldt RJ, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003; 22(1): 17-22.
59. Tojo A, Welch WJ, Bremer V, et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997; 52(6): 1593-1601.
60. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007; 13(2):198-203.
61. Onozato ML, Tojo A, Leiper J, Fujita T, Palm F, Wilcox CS. Expression of NG,NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes 2008;57(1): 172-180.
62. Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989; 264(17): 10205-10209.
63. Forbes SP, Druhan LJ, Guzman JE, Parinandi N, Zhang L, Green-Church KB, Cardounel AJ. Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in no regulation. Biochemistry 2008; 47(6): 1819-1826.
64. Hong L, Fast W. Inhibition of human dimethylarginine dimethylaminohydrolase- 1 by S-nitroso-L-homocysteine and hydrogen peroxide. Analysis, quantification, and implications for hyperhomocysteinemia. J Biol Chem 2007; 282(48): 34684-34692.
65. Achan V, Tran CT, Arrigoni F, Whitley GS, Leiper JM, Vallance P. All-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 2002; 90(7): 764-769.
66. Wang J, Sim AS, Wang XL, Wilcken DE. L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells. Cell Mol Life Sci 2006; 63(23): 2838-2846.
67. Schulman SP, Becker LC, Kass DA, et al. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 2006; 295(1): 58-64.
68. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002; 99(21): 13527-13532.
69. Sakurada M, Shichiri M, Imamura M, Azuma H, Hirata Y. Nitric oxide upregulates dimethylarginine dimethylaminohydrolase-2 via cyclic GMP induction in endothelial cells. Hypertension 2008; 52(5): 903-909.
70. Holden DP, Cartwright JE, Nussey SS, Whitley GS. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation 2003; 108(13): 1575-1580.
71. Monsalve E, Oviedo PJ, Garcia-Perez MA, Tarin JJ, Cano A, Hermenegildo C. Estradiol counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human endothelial cells. Cardiovasc Res 2007; 73(1): 66-72.
72. Eid HM, Lyberg T, Arnesen H, Seljeflot I. Insulin and adiponectin inhibit the TNFalpha-induced ADMA accumulation in human endothelial cells: the role of DDAH. Atherosclerosis 2007; 194(2):e1-e8.
73. Scalera F, Martens-Lobenhoffer J, Bukowska A, Lendeckel U, Tager M, Bode-Boger SM. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging. Hypertension 2008;51(3): 696-703.
74. Wakino S, Hayashi K. Anti-hypertensive effects of PPARgamma ligands through the inhibition of Rho/Rho kinase pathway. Nippon Rinsho 2005; 63(4): 693-699.
75. Tanaka M, Osanai T, Murakami R, et al. Effect of vasoconstrictor coupling factor 6 on gene expression profile in human vascular endothelial cells: enhanced release of asymmetric dimethylarginine. J Hypertens 2006; 24(3): 489-497.
76. Xin HY, Jiang DJ, Jia SJ, et al. Regulation by DDAH/ADMA pathway of lipopolysaccharide-induced tissue factor expression in endothelial cells. Thromb Haemost 2007; 97(5): 830-838.
77. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99(24): 3092-3095.
78. Wadham C, Mangoni AA. Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease. Expert Opin Drug Metab Toxicol 2009; 5(3): 303-319.
79. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95(8): 2068-2074.
80. Kielstein JT, Impraim B, Simmel S, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109(2): 172-177.
81. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99(9): 1141-1146.
82. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358(9299): 2127-2128.
83. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001; 158(2): 425-430.
84. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358(9299): 2113-2117.
85. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98(18): 1842-1847.
86. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38(1): 111-116.
87. Sydow K, Schwedhelm E, Arakawa N, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e) inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003; 57(1): 244-252.
88. Wang D, Gill PS, Chabrashvili T, et al. Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endotheliumderived relaxing factor/NO. Circ Res 2007; 101(6): 627-635.
89. Smith CL, Birdsey GM, Anthony S, Arrigoni FI, Leiper JM, Vallance P. Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype. Biochem Biophys Res Commun 2003; 308(4): 984-989.
90. Kostourou V, Robinson SP, Cartwright JE, Whitley GS. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. British journal of cancer 2002; 87(6): 673-680.
91. Konishi H, Sydow K, Cooke JP. Dimethylarginine dimethylaminohydrolase promotes endothelial repair after vascular injury. J Am Coll Cardiol 2007; 49(10): 1099-1105.
92. Wojciak-Stothard B, Torondel B, Tsang LY, et al. The ADMA/ DDAH pathway is a critical regulator of endothelial cell motility. J Cell Sci 2007; 120(Pt 6): 929-942.
93. Achan V, Ho HK, Heeschen C, et al. ADMA regulates angiogenesis: genetic and metabolic evidence. Vasc Med 2005; 10(1): 7-14.
94. Hoefen RJ, Berk BC. The role of MAP kinases in endothelial activation. Vascul Pharmacol 2002; 38(5): 271-273.
95. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005; 46(9): 1693-1701.
96. Peterson DA, Peterson DC, Archer S, Weir EK. The non specificity of specific nitric oxide synthase inhibitors. Biochem Biophys Res Commun 1992; 187(2): 797-801.
97. Buxton IL, Cheek DJ, Eckman D, Westfall DP, Sanders KM, Keef KD. NG-nitro L-arginine methyl ester and other alkyl esters of arginine are muscarinic receptor antagonists. Circ Res 1993; 72(2):387-395.
98. Brusilow SW, Horwich AL. Urea cycle enzymes. In: Scriver CR, Ed. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill 1989: 629-663.
99. Jureti- A, Spagnoli GC, Hörig H, et al. Nitric oxide-independent inhibitory effects of L-arginineanalog NG-monomethy-L-arginine on the generation of interleukin-2 activated cytotoxic activity in humans. Clin Nutr 1996; 15(1): 16-20.
100. Matsumoto Y, Ueda S, Yamagishi S, et al. Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol 2007; 18(5): 1525-1533.
101. Suda O, Tsutsui M, Morishita T, et al. Long-term treatment with N(omega)-nitro-L-arginine methyl ester causes arteriosclerotic coronary lesions in endothelial nitric oxide synthase-deficient mice. Circulation 2002; 106(13): 1729-1735.
102. Suda O, Tsutsui M, Morishita T, et al. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthasedeficient mice: involvement of renin-angiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol 2004; 24(9): 1682-1688.
103. Hultstrom M, Helle F, Iversen BM. AT(1) receptor activation regulates the mRNA expression of CAT1, CAT2, arginase-1, and DDAH2 in preglomerular vessels from angiotensin II hypertensive rats. Am J Physiol Renal Physiol 2009; 297(1): F163-F168.
104. Helle F, Hultstrom M, Skogstrand T, Palm F, Iversen BM. Angiotensin II-induced contraction is attenuated by nitric oxide in afferent arterioles from the nonclipped kidney in 2K1C. Am J Physiol Renal Physiol 2009; 296(1): F78-F86.
105. Tran CT, Leiper JM, Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 2003; 4(4): 33-40.
106. Mookerjee RP, Malaki M, Davies NA, et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 2007; 45(1): 62-71.
107. Nijveldt RJ, Teerlink T, Van Der Hoven B, et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003; 22(1): 23-30.
108. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2006; 2(4): 209-220.
109. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. Nephrol Dial Transplant 2006; 21(9):2446-2451.
110. Matsuguma K, Ueda S, Yamagishi S, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006; 17(8):2176-2183.
111. Kielstein JT, Boger RH, Bode-Boger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13(1): 170-176.
112. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16(8):2456-2461.
113. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 1998; 32(6): 958-964.
114. Kang DH, Nakagawa T, Feng L, Johnson RJ. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 2002; 161(1): 239-248.
115. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16(8): 2449-2455.
116. Abedini S, Meinitzer A, Holme I, et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 2010;77(1): 44-50.
117. Chan CT, Harvey PJ, Boger R, Pierratos A, Floras JS. Dissociation between the short-term effects of nocturnal hemodialysis on endothelium dependent vasodilation and plasma ADMA. Arterioscler Thromb Vasc Biol 2005; 25(12): 2685-2686.
118. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356(9224): 147-152.
119. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23(2): 233-246.
120. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117(6): 743-753.
121. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11(9): 1735-1743.
122. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004; 66(1): 441-447.
123. Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DE. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 2006; 184(2):383-388.
124. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13(2): 490-496.
125. Lentz SR, Rodionov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atheroscler Suppl 2003; 4(4): 61-55.
126. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20(6): 1557-1564.
127. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23(8): 1455-1459.
128. Maas R, Schulze F, Baumert J, et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem 2007; 53(4): 693-701.
129. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease:results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006; 152(3): 493 e1-e8.
130. Stuhlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 2003; 108(8): 933-938.
131. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104(21): 2569-2575.
132. Mato JM, Lu SC. Homocysteine, the bad thiol. Hepatology 2005; 41(5): 976-979.
133. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 2001; 100(2): 161-167.
134. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis 2007; 49(1): 12-26.
135. Abdelwhab S, Lotfy G, Abdelmaksoud S. Relation between asymmetric dimethylarginine (ADMA) and hearing loss in patients with renal impairment. Ren Fail 2008; 30(9): 877-883.
136. Stefanadi E, Tousoulis D, Papageorgiou N, Briasoulis A, Stefanadis C. Inflammatory biomarkers predicting events in atherosclerosis. Curr Med Chem 2010; 17(16): 1690-1707.
137. Dominiczak AF, Bohr DF. Nitric oxide and its putative role in hypertension. Hypertension 1995; 25(6): 1202-1211.
138. Arnal JF MJ, Harrison DG. Nitric oxide in the pathogenesis of hypertension. Curr Opin Nephrol Hypertens 1995; 4(2): 182-188.
139. Curgunlu A, Uzun H, Bavunoglu I, Karter Y, Genc H, Vehid S. Increased circulating concentrations of asymmetric dimethylarginine (ADMA) in white coat hypertension. J Hum Hypertens 2005;19(8): 629-633.
140. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Reninangiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J 2001; 65(9): 775-778.
141. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46(3): 518-523.
142. Surdacki A, Nowicki M, Sandmann J, et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33(4): 652-658.
143. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Boger RH. Determination of a reference value for N(G), N(G)-dimethyl- L-arginine in 500 subjects. Eur J Clin Invest 2005; 35(10): 622-626.
144. Paiva H, Laakso J, Kahonen M, et al. Asymmetric dimethylarginine and hemodynamic regulation in middle-aged men. Metabolism 2006; 55(6): 771-777.
145. Xia W, Feng W, Guan M, Yu Y, Li J, Qu X. Increased levels of asymmetric dimethylarginine and C-reactive protein are associated with impaired vascular reactivity in essential hypertension. Clin Exp Hypertens 2010; 32(1): 43-48.
146. Wang D, Strandgaard S, Iversen J, Wilcox CS. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol 2009; 296(2): R195-R200.
147. Leonard AM, Chafe LL, Montani JP, Van Vliet BN. Increased salt sensitivity in endothelial nitric oxide synthase-knockout mice. Am J Hypertens 2006; 19(12): 1264-1269.
148. Carlstrom M, Brown RD, Edlund J, et al. Role of nitric oxide deficiency in the development of hypertension in hydronephrotic animals. Am J Physiol Renal Physiol 2008; 294(2): F362-370.
149. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112(5): 666-673.
150. Reaven GM, Chen YD. Role of abnormal free fatty acid metabolism in the development of non-insulin-dependent diabetes mellitus. Am J Med 1988; 85(5A): 106-112.
151. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003; 88(6): 2399-2403.
152. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005; 46(11): 1978-1985.
153. Frisbee JC, Samora JB, Peterson J, Bryner R. Exercise training blunts microvascular rarefaction in the metabolic syndrome. Am J Physiol Heart Circ Physiol 2006; 291(5): H2483-H2492.
154. Roberts CK, Barnard RJ, Sindhu RK, Jurczak M, Ehdaie A, Vaziri ND. A high-fat, refined-carbohydrate diet induces endothelial dysfunction and oxidant/antioxidant imbalance and depresses NOS protein expression. J Appl Physiol 2005; 98(1): 203-210.
155. Roberts CK, Vaziri ND, Wang XQ, Barnard RJ. Enhanced NO inactivation and hypertension induced by a high-fat, refinedcarbohydrate diet. Hypertension 2000; 36(3): 423-429.
156. Sun YX, Hu SJ, Zhang XH, Sun J, Zhu CH, Zhang ZJ. Plasma levels of vWF and NO in patients with metabolic syndrome and their relationship with metabolic disorders. Zhejiang da xue xue bao Yi xue ban = J Zhejiang Univ 2006; 35(3): 315-318.
157. Tesauro M, Schinzari F, Iantorno M, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 2005; 112(19): 2986-2992.
158. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287(11): 1420-1426.
159. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001;86(8): 3574-3578.
160. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004; 94(2):157-161.
161. Annuk M, Zilmer M, Fellstrom B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: impact on cardiovascular disease. Kidney Int Suppl 2003; (84): S50-S53.
162. Laakso M. Hyperglycemia as a risk factor for cardiovascular disease in type 2 diabetes. Prim Care 1999; 26(4): 829-839.
163. Feher MD, Elkeles RS. Lipid modification and coronary heart disease in type 2 diabetes: different from the general population? Heart 1999; 81(1): 10-11.
164. Choi JW, Pai SH, Kim SK, Ito M, Park CS, Cha YN. Increases in nitric oxide concentrations correlate strongly with body fat in obese humans. Clin Chem 2001; 47(6): 1106-1109.
165. Baron AD, Clark MG. Role of blood flow in the regulation of muscle glucose uptake. Annu Rev Nutr 1997; 17: 487-499.
166. Montagnani M, Chen H, Barr VA, Quon MJ. Insulin-stimulated activation of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179). J Biol Chem 2001; 276(32): 30392-30398.
167. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294(1): E15-E26.
168. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98(4): 894-898.
169. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003; 92(4A): 10J-17J.
170. Gonzalez M, Flores C, Pearson JD, Casanello P, Sobrevia L. Cell signalling-mediating insulin increase of mRNA expression for cationic amino acid transporters-1 and -2 and membrane hyperpolarization in human umbilical vein endothelial cells. Pflugers Arch 2004; 448(4): 383-394.
171. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002; 106(8): 987-992.
172. Xiong Y, Fu YF, Fu SH, Zhou HH. Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes. J Cardiovasc Pharmacol 2003; 42(2): 191-196.
173. Abbasi F, Asagmi T, Cooke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88(10): 1201-1203.
174. Paiva H, Lehtimaki T, Laakso J, et al. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003; 52(3): 303-307.
175. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004; 27(3): 765-769.
176. McLaughlin T, Stuhlinger M, Lamendola C, et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab 2006; 91(5): 1896-1900.
177. Krzyzanowska K, Mittermayer F, Kopp HP, Wolzt M, Schernthaner G. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab 2004; 89(12): 6277-6281.
178. Abhary S, Burdon KP, Kuot A, et al. Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes. PLoS One 2010; 5(3): e9462.
179. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113(15): 1888-1904.
180. Ellger B, Debaveye Y, Vanhorebeek I, et al. Survival benefits of intensive insulin therapy in critical illness: impact of maintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes 2006; 55(4): 1096-1105.
181. Sorrenti V, Mazza F, Campisi A, Vanella L, Li Volti G, Di Giacomo C. High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells. Curr Neurovasc Res 2006; 3(1): 49-54.
182. Ellger B, Richir MC, van Leeuwen PA, et al. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity. Endocrinology 2008; 149(6): 3148-3157.
183. Devangelio E, Santilli F, Formoso G, et al. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 2007; 43(4): 511-518.
184. Santilli F, Bucciarelli L, Noto D, et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 2007; 43(9): 1255-1262.
185. Lai YL, Aoyama S, Nagai R, Miyoshi N, Ohshima H. Inhibition of L-arginine metabolizing enzymes by L-arginine-derived advanced glycation end products. J Clin Biochem Nutr 2010; 46(2): 177-185.
186. Yin QF, Xiong Y. Pravastatin restores DDAH activity and endothelium-dependent relaxation of rat aorta after exposure to glycated protein. J Cardiovasc Pharmacol Res 2005; 45(6): 525-532.
187. Kielstein JT, Bode-Boger SM, Frolich JC, Haller H, Boger RH. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int Suppl 2001; 78: S9-S13.
188. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003; 4(4): 41-51.
189. Munzel T, Keaney JF, Jr. Are ACE inhibitors a magic bullet against oxidative stress? Circulation 2001; 104(13): 1571-1574.
190. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1- receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002; 15(7 Pt 1): 590-593.
191. Galle J, Schwedhelm E, Pinnetti S, Boger RH, Wanner C. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008; 23(10): 3174-3183.
192. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97(12): 1129-1135.
193. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20(1): 61-69.
194. Young JM, Strey CH, George PM, et al. Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with nonischaemic heart failure. Eur J Heart Fail 2008; 10(5): 463-466.
195. Nanayakkara PW, Kiefte-de Jong JC, ter Wee PM, et al. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD. Am J Kidney Dis 2009; 53(1): 41-50.
196. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001; 88(5): 504-508.
197. Jones SP, Gibson MF, Rimmer DM, 3rd, Gibson TM, Sharp BR, Lefer DJ. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 2002; 40(6): 1172-1178.
198. Ivashchenko CY, Bradley BT, Ao Z, Leiper J, Vallance P, Johns DG. Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the sterol response element binding proteins, SREBP1c and -2. Am J Physiol Heart Circ Physiol 2010; 298(1): H251-H258.
199. Katagiri H, Yamada T, Oka Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ Res 2007; 101(1): 27-39.
200. Lacy F, O'Connor DT, Schmid-Schonbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 1998; 16(3): 291-303.
201. Jun T, Ke-yan F, Catalano M. Increased superoxide anion production in humans: a possible mechanism for the pathogenesis of hypertension. J Hum Hypertens 1996; 10(5): 305-309.
202. Jiang JL, Li Ns NS, Li YJ, Deng HW. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 2002; 135(5): 1175-1182.
203. Wu QD, Wang JH, Fennessy F, Redmond HP, Bouchier-Hayes D. Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis. Am J Physiol 1999; 277(6 Pt 1): C1229-C1238.
204. Sener G, Ozer Sehirli A, Ipci Y,. Taurine treatment protects against chronic nicotine-induced oxidative changes. Fundam Clin Pharmacol 2005; 19(2): 155-164.
205. Tan B, Jiang DJ, Huang H,. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway. Vasc Pharmacol 2007; 46(5): 338-345.
206. Xiao HB, Jun F, Lu XY, Chen XJ, Chao T, Sun ZL. Protective effects of kaempferol against endothelial damage by an improvement in nitric oxide production and a decrease in asymmetric dimethylarginine level. Eur J Pharmacol 2009; 616(1-3): 213-222.
207. Maret W. Zinc coordination environments in proteins as redox sensors and signal transducers. Antioxid Redox Signal 2006; 8(9-10): 1419-1441.
208. Rios-Vazquez R, Marzoa-Rivas R, Gil-Ortega I, Kaski JC. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs 2006; 6(4): 231-242.
209. Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95(2): 592-600.
210. Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF, Lee YT. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2006; 98(8):1057-1062.
211. Savoia C, Ebrahimian T, Lemarie CA. Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1. Clin Sci (Lond) 2010; 118(9): 583-592.
212. Kelly AS, Thelen AM, Kaiser DR, Gonzalez-Campoy JM, Bank AJ. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med 2007; 12(4): 311-318.
213. Richir MC, Ellger B, Teerlink T, et al. The effect of rosiglitazone on asymmetric dimethylarginine (ADMA) in critically ill patients. Pharmacol Res 2009; 60(6): 519-524.
214. Mittermayer F, Schaller G, Pleiner J, et al. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J Clin Endocrinol Metab 2007; 92(7): 2574-2580.
215. Khan NA, Wiernsperger N, Quemener V, Havouis R, Moulinoux JP. Characterization of metformin transport system in NIH 3T3 cells. J Cell Physiol 1992; 152(2): 310-316.
216. Asagami T, Abbasi F, Stuelinger M, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51(7): 843-846.
217. Heutling D, Schulz H, Nickel I, et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008; 93(1): 82-90.
218. Ozgurtas T, Oktenli C, Dede M, et al. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis 2008; 200(2): 336-344.
219. Marcovecchio ML, Widmer B, Dunger DB, Dalton RN. Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with Type 1 diabetes. Clin Sci (Lond) 2008; 115(12): 361-369.
220. Sydow K, Mondon CE, Schrader J, Konishi H, Cooke JP. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler Thromb Vasc Biol 2008; 28(4): 692-697.
221. Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993;87(5): 1475-1481.
222. Nitenberg A, Paycha F, Ledoux S, Sachs R, Attali JR, Valensi P. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation 1998; 97(8): 736-743.
223. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90(4):1248-1253.
224. Preli RB, Klein KP, Herrington DM. Vascular effects of dietary Larginine supplementation. Atherosclerosis 2002; 162(1): 1-15.
225. Blum A, Hathaway L, Mincemoyer R, et al. 3rd. Effects of oral Larginine on endothelium-dependent vasodilation and markers of inflammation in healthy postmenopausal women. J Am Coll Cardiol 2000; 35(2): 271-276.
226. Blum A, Hathaway L, Mincemoyer R, et al. Oral L-arginine in patients with coronary artery disease on medical management. Circulation 2000; 101(18): 2160-2164.
227. Chin-Dusting JP, Alexander CT, Arnold PJ, Hodgson WC, Lux AS, Jennings GL. Effects of in vivo and in vitro L-arginine supplementation on healthy human vessels. J Cardiovasc Pharmacol 1996; 28(1): 158-166.
228. Chin-Dusting JP, Kaye DM, Lefkovits J, Wong J, Bergin P, Jennings GL. Dietary supplementation with L-arginine fails to re store endothelial function in forearm resistance arteries of patients with severe heart failure. J Am Coll Cardiol 1996; 27(5): 1207-1213.
229. Wilcken DE, Sim AS, Wang J, Wang XL. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism. Mol Genet Metab 2007; 91(4): 309-317; discussion 8.
230. Deng S, Deng PY, Jiang JL, et al. Aspirin protected against endothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats. Acta Pharmacol Sin 2004; 25(12): 1633-1639.
231. Yang TL, Chen MF, Luo BL, Yu J, Jiang JL, Li YJ. Effect of fenofibrate on LDL-induced endothelial dysfunction in rats. Naunyn Schmiedebergs Arch Pharmacol 2004; 370(2): 79-83.
232. Mehta JL, Hu B, Chen J, Li D. Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol 2003; 23(12): 2203-2208.
233. Wakino S, Hayashi K, Tatematsu S, et al. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats. Hypertens Res 2005; 28(3):255-262.
234. Eid HM, Reims H, Arnesen H, Kjeldsen SE, Lyberg T, Seljeflot I. Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia. Metabolism 2007; 56(4): 464-469.